Marea key facts
- Operator of a biotechnology company intended for the treatment of cardiometabolic diseases.
- Marea’s last known valuation is $272.0M.
- It has raised $190.0M; the latest was Early Stage VC ($160.0M) in Jun 2024.
- Notable investors include Alpha Wave Global, Forbion, Perceptive Advisors, Omega Funds, Surveyor Capital — 9 tracked in total.
- Status: Privately Held (backing).
- ·Watch Marea: the Monday email on marks, rounds and moves
Marea funding rounds
No funding rounds for Marea are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Marea valuation
Marea's last known valuation is $272 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Marea investors
9 investors are on record for Marea, including Alpha Wave Global, Forbion, Perceptive Advisors and Omega Funds. By type, the record holds 3 venture capital firms, 2 hedge funds and 1 private equity firm.
About Marea
Operator of a biotechnology company intended for the treatment of cardiometabolic diseases. The company specializes in the development of novel therapies for patients at risk for heart attacks, enabling patients to reduce remnant cholesterol and metabolic dysfunction and enhance the overall efficiency of the treatment process.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2022
- Employees
- 32
- Website
- mareatx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Marea’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.